| Project Title | Prevalent and Incident Use of Generic Name Kinase Inhibitors |
| Date Posted | Thursday, March 8, 2018 |
| Project ID | to16_cap_str_wp003-006_nsdp_v01 |
| Status | In progress |
| Deliverables | |
| Description | These reports look at the prevalent and incident use of 27 kinase inhibitors in the Mini-Sentinel Distributed Database (MSDD). These results were generated using the Mini-Sentinel Distributed Query Tool. These queries were run against the Dispensing Summary Table and distributed on November 14, 2014 to 14 Data Partners; these reports include information from 14 Data Partners. |
| Medical Product | afatinib dimaleate axitinib bortezomib cabozantinib s-malate carfilzomib ceritinib crizotinib dabrafenib mesylate dasatinib erlotinib HCL everolimus gefitinib ibrutinib idelalisib imatinib mesylate lapatinib ditosylate nilotinib HCL pazopanib HCL ponatinib HCL regorafenib ruxolitinib phosphate sorafenib tosylate sunitinib malate trametinib dimethyl sulfoxide vandetanib vemurafenib |
| Population / Cohort | All individuals |
| Time Period | 2001-2014 |
| Assessment Type | Exploratory Analyses |
| Study Type | Summary Table |
| Data Sources | Mini-Sentinel Distributed Database (MSDD) |
| FDA Center | CDER |
